In these pre-clinical studies, two monoclonal antibodies in development depleted targeted B-cells, without significantly affecting the non-targeted B-cells. Results for both studies showed that the number of target
Although enrollment was completed at the end of September 2007, three patients with stable disease continue to receive CTCE-9908 therapy. One patient with small bowel carcinoma is now
The double-blind, placebo-controlled study is the first study to measure the safety and efficacy of a PDE 5 inhibitor in a cohort of men who all had erectile
This double-blind, placebo-controlled trial enrolled normal healthy adult volunteers in sequential, dose-escalating cohorts. The Phase I data show that single, oral doses of NGX426 from 40mg to 90mg
Testing of the lead candidates in treated leukemia cell cultures indicated that the JAK2 kinase inhibitors were active against both wild-type and mutant JAK2 kinase activity and caused
Of the 73 evaluable cutaneous T-cell lymphoma (CTCL) patients, an overall response rate of 37% (27/73) was reported, with four complete responses (6%), 23 partial responses (31%) and
The study demonstrated that the uptake, efflux and cytotoxicity of Xanafide were unaffected by MDR proteins expressed in acute myeloid leukemia (AML) cells, and s-AML cells in particular,
In the study, Inno-406 was shown to be well tolerated and demonstrated activity in patients with chronic myelogenous leukemia (CML) who are intolerant or resistant to imatinib and
The acquisition will bring together ImmunoVaccine Technologies (IVT’s) signature VacciMax platform with Immunotope’s portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create
These results suggest that a single, confirmatory, Phase III clinical trial could provide sufficient evidence of efficacy provided that it is well designed, well executed and provides clinically
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.